×
About 863,034 results

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent a...
https://doi.org/10.1016/S1474-4422(14)70053-5
The Lancet. Neurology; Michelson D, Snyder E et. al.

Mar 31st, 2014 - Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. We aimed to assess its clinical profile during and after 1 year of treatment. We did a randomised, placebo-controlled, parallel-group trial at 106 investigational centres in the Americas, Australia, Europe, and South Africa from December, 2009, to August, 2011. Patients aged 18 years or old...

Omalizumab therapy for bullous pemphigoid.
https://doi.org/10.1016/j.jaad.2014.04.053
Journal of the American Academy of Dermatology; Yu KK, Crew AB et. al.

Jun 23rd, 2014 - Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents and usually controls, but does not cure, the disease. Omalizumab, Food and Drug Administration-approved for asthma, selectively suppresses the activity of IgE, an important immunoglobulin in the pathogenesis of BP. We wished to determine if systemic omalizumab would have a therapeutic effect in patients with BP. We treate...

Inhibition of the mTORC pathway in the antiphospholipid syndrome.
https://doi.org/10.1056/NEJMoa1312890
The New England Journal of Medicine; Canaud G, Bienaimé F et. al.

Jul 23rd, 2014 - Although thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly in patients with life-threatening complications. In patients who require transplantation, vascular lesions often recur. The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate therapies are lacking. We u...

Spread of artemisinin resistance in Plasmodium falciparum malaria.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143591
The New England Journal of Medicine; Ashley EA, Dhorda M et. al.

Jul 30th, 2014 - Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15...

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
https://doi.org/10.1056/NEJMoa1313865
The New England Journal of Medicine; Diacon AH, Pym A et. al.

Aug 20th, 2014 - Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP synthase, has been associated with accelerated sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a preferred background regimen for 8 weeks. In this phase 2b trial, we randomly assigned 160 patients with newly diagnosed, smear-positive, multidrug-resistant tuberculosis to re...

Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159743
Neuron Tang G, Gudsnuk K et. al.

Aug 26th, 2014 - Developmental alterations of excitatory synapses are implicated in autism spectrum disorders (ASDs). Here, we report increased dendritic spine density with reduced developmental spine pruning in layer V pyramidal neurons in postmortem ASD temporal lobe. These spine deficits correlate with hyperactivated mTOR and impaired autophagy. In Tsc2 ± ASD mice where mTOR is constitutively overactive, we ...

Ivabradine in stable coronary artery disease without clinical heart failure.
https://doi.org/10.1056/NEJMoa1406430
The New England Journal of Medicine; Fox K, Ford I et. al.

Sep 1st, 2014 - An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standar...

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related pept...
https://doi.org/10.1016/S1474-4422(14)70128-0
The Lancet. Neurology; Dodick DW, Goadsby PJ et. al.

Aug 15th, 2014 - Migraine remains poorly treated, with few effective preventive drugs available. We assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention. We did a randomised, double-blind, placebo-controlled, phase 2 proof-of-concept study at 35 centres in the USA. Patients aged 18-65 years with four to 14 migraine heada...

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362521
Nature Medicine; Xing L, Dai Z et. al.

Aug 18th, 2014 - Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. The immune pathways required for autoreactive T cell activation in AA are not defined limiting clinical development of rational targeted therapies. Genome-wide association studies (GWAS) implicated ligands for the NKG2D receptor (product of the KLRK1 gene) in disease pathogenesis. Here, we...

New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associate...
https://doi.org/10.1001/jama.2014.12720
JAMA Epstein L, Hunter JC et. al.

Oct 7th, 2014 - Carbapenem-resistant Enterobacteriaceae (CRE) producing the New Delhi metallo-β-lactamase (NDM) are rare in the United States, but have the potential to add to the increasing CRE burden. Previous NDM-producing CRE clusters have been attributed to person-to-person transmission in health care facilities. To identify a source for, and interrupt transmission of, NDM-producing CRE in a northeastern ...

Ketamine and intraocular pressure in children.
https://doi.org/10.1016/j.annemergmed.2014.01.029
Annals of Emergency Medicine; Wadia S, Bhola R et. al.

Mar 3rd, 2014 - We determine the increase in intraocular pressure during pediatric procedural sedation with ketamine, and the proportion of children whose increase might be clinically important (at least 5 mm Hg). We prospectively enrolled children aged 8 to 18 years, chosen to receive ketamine sedation in a pediatric emergency department. We measured intraocular pressure before sedation, immediately after ket...

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patient...
https://doi.org/10.1016/S1470-2045(17)30171-7
The Lancet. Oncology; Schreuer M, Jansen Y et. al.

Mar 7th, 2017 - Patients with BRAFV600-mutant melanoma benefit from treatment with the combination of BRAF and MEK inhibitors, but resistance and disease progression develops in most patients. Preclinical studies and case studies have indicated that acquired resistance to BRAF inhibition can be reversible. We aimed to assess the anti-tumour activity of rechallenge with BRAF plus MEK inhibition in a prospective...

Interactions between cannabidiol and commonly used antiepileptic drugs.
https://doi.org/10.1111/epi.13852
Epilepsia Gaston TE, Bebin EM et. al.

Aug 6th, 2017 - To identify potential pharmacokinetic interactions between the pharmaceutical formulation of cannabidiol (CBD; Epidiolex) and the commonly used antiepileptic drugs (AEDs) through an open-label safety study. Serum levels were monitored to identify interactions between CBD and AEDs. In 39 adults and 42 children, CBD dose was started at 5 mg/kg/day and increased every 2 weeks by 5 mg/kg/day up to ...

Longitudinal recovery patterns of penile length and the underexplored benefit of long-t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941788
BMC Urology; Kwon YS, Farber N et. al.

May 9th, 2018 - Penile length (PL) shortening is an underreported phenomenon following radical prostatectomy (RP) and risk factors are not fully explored. We aimed to describe longitudinal patterns of PL recovery and evaluate factors predicting complete return to baseline PL. PL measurement was performed during a preoperative and postoperative follow-up visits at 7 days and 3, 6, 9, and 12 months. Patients who...

Topical tetracaine used for 24 hours is safe and rated highly effective by patients for...
https://doi.org/10.1111/acem.12346
Academic Emergency Medicine : Official Journal of the Soc... Waldman N, Densie IK et. al.

Apr 15th, 2014 - The objective of this study was to test the hypothesis that topical tetracaine would be safe to use for 24 hours and would not affect corneal healing, that patients would experience more pain relief, and that patients would perceive tetracaine to be more effective than saline eye drops for the treatment of pain caused by corneal abrasions. The study was a 12-month, prospective, double-blind, ra...

Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365950
Circulation Cavender MA, Scirica BM et. al.

Feb 14th, 2015 - Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus (DM) are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from antithrombotic therapies. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Ev...

Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe...
https://doi.org/10.1001/jamapsychiatry.2014.2162
JAMA Psychiatry; McElroy SL, Hudson JI et. al.

Jan 14th, 2015 - Binge-eating disorder (BED), a public health problem associated with psychopathological symptoms and obesity and possibly with metabolic syndrome, lacks approved pharmacotherapies. To examine the efficacy and safety of lisdexamfetamine dimesylate, a dextroamphetamine prodrug, to treat moderate to severe BED. We performed a randomized, double-blind, parallel-group, forced dose titration, placebo...

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358820
The New England Journal of Medicine; Vannucchi AM, Kiladjian JJ et. al.

Jan 29th, 2015 - Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea. We randomly assig...

Anhedonia as a component of the tobacco withdrawal syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348025
Journal of Abnormal Psychology; Cook JW, Piper ME et. al.

Nov 10th, 2014 - Animal research suggests that anhedonia is a tobacco withdrawal symptom, but this topic has not been addressed definitively in research with humans. This research sought to determine whether anhedonia is (a) an element of the tobacco withdrawal syndrome in humans and (b) an impediment to successful tobacco cessation. Data were from 1,175 smokers (58.3% women; 85.5% White) participating in a ran...

Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962880
JAMA Mistry PK, Lukina E et. al.

Feb 17th, 2015 - Gaucher disease type 1 is characterized by hepatosplenomegaly, anemia, thrombocytopenia, and skeletal disease. A safe, effective oral therapy is needed. To determine whether eliglustat, a novel oral substrate reduction therapy, safely reverses clinical manifestations in untreated adults with Gaucher disease type 1. Phase 3, randomized, double-blind, placebo-controlled trial conducted at 18 site...